KOL Insight - Multiple Myeloma

This report examines how key developments in multiple myeloma-ranging from anti-CD38 therapies and CAR T-cell treatments to bispecific antibodies and antibody-drug conjugates-are shaping current and future treatment pathways. Based on interviews with 12 KOLs in the US and Europe, it explores the potential expansion of Darzalex, the growing role of BCMA-targeting CAR T-cell therapies, and the outlook for pipeline candidates from Gilead/Arcellx, CARsgen, and AstraZeneca. It also considers the positioning of bispecific antibodies such as Tecvayli and Elrexfio, and the re-emergence of GSK's Blenrep, as clinicians weigh up evolving efficacy and safety profiles. Gain a clearer view of how the myeloma treatment landscape is expected to evolve over the next 3-5 years.

Key Questions Answered:

• 1. What are the biggest drivers of change in myeloma treatment over the next 3-5 years?
• 2. Could Darzalex play a meaningful role in treating high-risk smouldering myeloma?
• 3. How is Darzalex's position evolving across newly diagnosed and relapsed settings?
• 4. Can Sarclisa compete with Darzalex, and will a subcutaneous option boost its uptake?
• 5. How do KOLs view iberdomide and mezigdomide compared to older IMiDs?
• 6. How will the use of CAR T-cell therapies shift in the near term?
• 7. What is the outlook for BCMA-directed bispecific antibodies in earlier lines of therapy?
• 8. Will Blenrep's re-entry into the market be welcomed despite ocular toxicity concerns?

Key Brands:

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.